🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 55083R203 (prev. 55083R104 )
- IPO
- 6/17/2021 · $17.00/share
Business: Lyell Immunopharma, Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. They apply proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Company Contact
- CEO
- Lynn Seely
- CFO
- Charles Newton
- Headquarters
- 201 Haskins Way, South San Francisco, CA 94080
- Phone
- 650-695-0677
- Investor Relations
- Heather Turner · 650-695-0677 · IR@lyell.com